CENTRILLION BIOSCIENCES, INC.

Biotech · Private

Oligonucleotide chip platform that stretches and immobilizes individual DNA molecules for improved whole genome sequencing with structural variant detection and haplotype phasing

centrillionbio.com →
Grants
$954K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Phased Sequencing of Complete Genomes via DNA Barcode Array$652,000
Federal grantDepartment of Health and Human Services · Phase I · Phased Sequencing of Complete Genomes via DNA Barcode Array$302,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2822Neurogene Inc.—$106M
2823Ovid Therapeutics—$106M
2824LEAP THERAPEUTICS, INC.—$105M
2825CENTRILLION BIOSCIENCES, INC.——
2826Adaptimmune—$104M
2827Civitas Therapeutics—$104M
2828AVATAR MEDICAL, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.